Rincell 1
Alternative Names: Rincell-1Latest Information Update: 08 Nov 2025
At a glance
- Originator Innovate UK; University of Sheffield
- Developer Rinri Therapeutics
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Sensorineural hearing loss
Most Recent Events
- 01 Jul 2025 Preclinical trials in Sensorineural hearing loss in United Kingdom (Parenteral)
- 01 Jul 2025 Rinri Therapeutics approves Clinical Trial Application (CTA) from the UK MHRA for phase I/IIa trial in Sensorineural hearing loss in United Kingdom (Rinri Therapeutics pipeline, July 2025)
- 01 Jul 2025 Rinri Therapeutics plans (CTA) phase I/IIa trial in Sensorineural hearing loss in United Kingdom (Rinri Therapeutics pipeline, July 2025)